Last reviewed · How we verify
Triamcinolone plus hyruan
Triamcinolone plus hyruan is a Corticosteroid + viscoelastic agent combination Small molecule drug developed by Taipei Medical University. It is currently FDA-approved for Osteoarthritis or joint inflammation (intra-articular injection), Soft tissue inflammation and pain. Also known as: corticosteroids plus hyaluronic acid.
Triamcinolone reduces inflammation via glucocorticoid receptor activation, while hyaluronic acid (hyruan) provides lubrication and tissue protection through its viscoelastic properties.
Triamcinolone is a glucocorticoid receptor agonist, classified as a small molecule. It has been studied in combination with sodium hyaluronate (Hyruan) for treating conditions such as adhesive capsulitis and knee osteoarthritis.
At a glance
| Generic name | Triamcinolone plus hyruan |
|---|---|
| Also known as | corticosteroids plus hyaluronic acid |
| Sponsor | Taipei Medical University |
| Drug class | Corticosteroid + viscoelastic agent combination |
| Target | Glucocorticoid receptor (triamcinolone); hyaluronic acid receptor (CD44, RHAMM) for hyruan |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Orthopedics |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone is a corticosteroid that suppresses inflammatory cytokines and immune cell infiltration. Hyaluronic acid is a naturally occurring polysaccharide that acts as a lubricant and protective agent in joints and tissues. The combination leverages anti-inflammatory and protective mechanisms for joint or soft tissue disorders.
Approved indications
- Osteoarthritis or joint inflammation (intra-articular injection)
- Soft tissue inflammation and pain
Common side effects
- Local injection site pain or swelling
- Transient increase in joint pain (post-injection flare)
- Infection at injection site
- Systemic corticosteroid effects (with repeated dosing)
Key clinical trials
- Is Combined Steroid and Sodium Hyaluronate Hydrodilatation More Effective Than Isolated Steroid Hydrodilatation in Treating Patients With Adhesive Capsulitis (NA)
- Effects of Knee Injections on Patients With Knee Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone plus hyruan CI brief — competitive landscape report
- Triamcinolone plus hyruan updates RSS · CI watch RSS
- Taipei Medical University portfolio CI
Frequently asked questions about Triamcinolone plus hyruan
What is Triamcinolone plus hyruan?
How does Triamcinolone plus hyruan work?
What is Triamcinolone plus hyruan used for?
Who makes Triamcinolone plus hyruan?
Is Triamcinolone plus hyruan also known as anything else?
What drug class is Triamcinolone plus hyruan in?
What development phase is Triamcinolone plus hyruan in?
What are the side effects of Triamcinolone plus hyruan?
What does Triamcinolone plus hyruan target?
Related
- Drug class: All Corticosteroid + viscoelastic agent combination drugs
- Target: All drugs targeting Glucocorticoid receptor (triamcinolone); hyaluronic acid receptor (CD44, RHAMM) for hyruan
- Manufacturer: Taipei Medical University — full pipeline
- Therapeutic area: All drugs in Rheumatology / Orthopedics
- Indication: Drugs for Osteoarthritis or joint inflammation (intra-articular injection)
- Indication: Drugs for Soft tissue inflammation and pain
- Also known as: corticosteroids plus hyaluronic acid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing